Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Internationally accepted pharmaceutical GDP regulations stipulate that distributors of pharmaceutical products and warehouses must align their operations with the specified standards
It will be the first and only global office for traditional medicine in the world
Routine tests undertaken by women dropped by 35% in 2020
Price was the key driver for the period
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Subscribe To Our Newsletter & Stay Updated
